Drugs / 18F-FPPRGD2
18F-FPPRGD2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01806675 | Mar 2013 → Dec 2016 | adenoid cystic carcinoma, adult glioblastoma, cancer of unknown primary site, carcinoma of lip +22 | Sanjiv Sam Gambhir | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02995642 | Oct 2019 → Sep 2020 | abdominal aortic aneurysm, atherosclerosis | Stanford University | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FPPRGD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01806675 ↗ |
| Known as | FPPRGD2 | “fluorine 18 ((18)F) 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2) positron emission tomography (PET)” PMID 25965900 ↗ May 2015 |
| Known as | PEG3-E[c{RGDyk}]2 | “fluorine 18 ((18)F) 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2) positron emission tomography (PET)” PMID 25965900 ↗ May 2015 |
| Modality | Diagnostic / imaging agent | “18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan” NCT01806675 ↗ |
| Route | Intravenous | “The study patients will receive an intravenous administration of 10mCi of the prescribed radiotracer (18F-FPPRGD2).” NCT02995642 ↗ |